Beranda › Astrositoma
Uji klinis Astrositoma yang merekrut di AS
45 studi untuk Astrositoma merekrut peserta di lokasi di seluruh Amerika Serikat.
Kota dengan studi terbanyak
- Houston, TX14 studi
- Boston, MA13 studi
- Chicago, IL9 studi
- New York City, NY9 studi
- Philadelphia, PA7 studi
- Miami, FL7 studi
- Columbus, OH6 studi
- Durham, NC6 studi
- Washington, DC6 studi
- Seattle, WA6 studi
- San Francisco, CA6 studi
- Aurora, CO5 studi
- Cincinnati, OH5 studi
- Salt Lake City, UT5 studi
- Baldwin Park, CA4 studi
- St. Louis, MO4 studi
- Birmingham, AL3 studi
- Ann Arbor, MI3 studi
- Lexington, KY3 studi
- Los Angeles, CA3 studi
- San Antonio, TX3 studi
- Edison, NJ3 studi
- Pittsburgh, PA3 studi
- Nashville, TN3 studi
- New Haven, CT3 studi
- Detroit, MI3 studi
- Dallas, TX3 studi
- Rochester, MN3 studi
- Kansas City, KS3 studi
- Queens, NY3 studi
Berdasarkan negara bagian
- Alabama3 studi
- California10 studi
- Colorado5 studi
- Connecticut3 studi
- Distrik Columbia4 studi
- Florida9 studi
- Georgia3 studi
- Illinois9 studi
- Kansas3 studi
- Kentucky4 studi
- Massachusetts13 studi
- Michigan6 studi
- Minnesota5 studi
- Missouri4 studi
- New Jersey3 studi
- New York9 studi
- North Carolina7 studi
- Ohio8 studi
- Pennsylvania8 studi
- Tennessee4 studi
- Texas15 studi
- Utah5 studi
- Virginia3 studi
- Washington7 studi
- Wisconsin3 studi
Studi yang baru diperbarui
Teks studi resmi (Bahasa Inggris)
Testing Addition of an Anti-cancer Drug, Vorasidenib to Temozolomide, After Radiation for Advanced Brain Cancer
Menerima pesertaFase 3
Usia 12 ke atas · Semua jenis kelamin · Diperbarui 2 Okt 2026 · NCT07215910GI-102 Alone or With Pembrolizumab Before Surgery for Treatment of Recurrent or Progressive IDH Wildtype Glioblastoma and IDH Mutated Grade 4 Astrocytoma
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 1 Okt 2026 · NCT07301268MSC-DNX-2401 in Treating Patients With Recurrent High-Grade Glioma
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 25 Sep 2026 · NCT03896568Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 24 Sep 2026 · NCT06047379A Study of Debio 0123 in Combination With Temozolomide in Adult Participants With Recurrent or Progressive Glioblastoma and of Debio 0123 in Combination With Temozolomide and Radiotherapy in Adult Participants With Newly Diagnosed Glioblastoma
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 22 Sep 2026 · NCT05765812VISTA: Valproic Acid, Irinotecan, and Simvastatin for Recurrent Glioma
Menerima pesertaFase 2
Usia 18 hingga 98 · Semua jenis kelamin · Diperbarui 21 Sep 2026 · NCT07831369A Study of Temodar With Abexinostat (PCI-24781) for Patients With Recurrent Glioma
Menerima pesertaFase 1
Usia 19 ke atas · Semua jenis kelamin · Diperbarui 14 Sep 2026 · NCT05698524SJ901: Evaluation of Mirdametinib in Children, Adolescents, and Young Adults With Low-Grade Glioma
Menerima pesertaFase 1/2
Usia 2 hingga 24 · Semua jenis kelamin · Diperbarui 11 Sep 2026 · NCT04923126FearLess in NeuroOncology
Menerima peserta
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 9 Sep 2026 · NCT06989086Targeted Pediatric High-Grade Glioma Therapy
Menerima pesertaStudi observasional
12 Months – 39 Years · Semua jenis kelamin · Diperbarui 8 Sep 2026 · NCT05839379HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors
Menerima pesertaFase 1
36 Months – 22 Years · Semua jenis kelamin · Diperbarui 4 Sep 2026 · NCT03911388Serial MRI Scans During Radiation Therapy
Menerima peserta
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 2 Sep 2026 · NCT04188535Testing the Addition of an Anti-Cancer Drug, Triapine, to the Usual Radiation Therapy for Recurrent Glioblastoma or Astrocytoma
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 2 Sep 2026 · NCT06860594Study of Olutasidenib and Temozolomide in HGG
Menerima pesertaFase 2
Usia 12 hingga 39 · Semua jenis kelamin · Diperbarui 1 Sep 2026 · NCT06161974SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 28 Agu 2026 · NCT05303519Hypofractionation Trial of Re-irradiation in Good Prognosis Recurrent Glioblastoma
Menerima pesertaFase 1
Usia 18 hingga 120 · Semua jenis kelamin · Diperbarui 14 Agu 2026 · NCT06344130Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies
Menerima pesertaFase 1/2
Usia 18 hingga 130 · Semua jenis kelamin · Diperbarui 12 Agu 2026 · NCT05417594Locoregional Administration of Genetically Engineered Cells (EGFR/IL13Rα2 Pool-CAR T Cells) for the Treatment of Recurrent or Progressive High-Grade Gliomas
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 12 Agu 2026 · NCT07544992Study of 203Pb-RMX-VH-PIB Dosimetry and Biodistribution in Patients With Glioblastoma Multiform (GBM) and Pancreatic Ductal Adenocarcinoma (PDAC)
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 7 Agu 2026 · NCT07733674Chemotherapy and Radiation Therapy for the Treatment of IDH Wildtype Gliomas or Non-histological (Molecular) Glioblastomas
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 16 Jul 2026 · NCT04623931Intracranial Genetically Modified Immune Cells (TGFβR2KO/IL13Rα2 CAR T-Cells) for the Treatment of Recurrent or Progressive Glioblastoma or Grade 3 or 4 IDH-Mutant Astrocytoma
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 29 Jun 2026 · NCT06815029Lorlatinib for Newly-Diagnosed High-Grade Glioma With ROS or ALK Fusion
Menerima pesertaFase awal 1Sukarelawan sehat diterima
Usia 1 hingga 21 · Semua jenis kelamin · Diperbarui 29 Jun 2026 · NCT06333899Retifanlimab With or Without Difluoromethylornithine for the Treatment of Progressive High Grade Gliomas
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 24 Jun 2026 · NCT07468136A Study of 177Lu-PSMA-617 in People With Gliomas
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 4 Jun 2026 · NCT07223034Loupe-Based Intraoperative Fluorescence Imaging
Menerima pesertaStudi observasional
Usia 18 hingga 90 · Semua jenis kelamin · Diperbarui 3 Jun 2026 · NCT04780009Dari ClinicalTrials.gov, data diambil 3 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.